tradingkey.logo
tradingkey.logo
Buscar

Genfit SA

GNFT
Añadir a la lista de seguimiento
4.850USD
0.0000.00%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
741.27MCap. mercado
--P/E TTM

Más Datos de Genfit SA Compañía

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Información de Genfit SA

Símbolo de cotizaciónGNFT
Nombre de la empresaGenfit SA
Fecha de salida a bolsaDec 19, 2006
Director ejecutivoPrigent (Pascal)
Número de empleados180
Tipo de seguridadDepository Receipt
Fin del año fiscalDec 19
DirecciónParc Eurasante 885 avenue Eugene Avinee
CiudadLOOS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal59120
Teléfono33320164000
Sitio Webhttps://www.genfit.fr/
Símbolo de cotizaciónGNFT
Fecha de salida a bolsaDec 19, 2006
Director ejecutivoPrigent (Pascal)

Ejecutivos de Genfit SA

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mrs. Anne-Helene Monsellato
Mrs. Anne-Helene Monsellato
Independent Director
Independent Director
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Eric Baclet
Mr. Eric Baclet
Independent Vice-Chairman of the Board of Directors
Independent Vice-Chairman of the Board of Directors
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Genfit SA?

Los cinco principales accionistas de Genfit SA son: Mr. Jean-Francois Mouney

¿Cuántas instituciones poseen acciones de Genfit SA (GNFT)?

A fecha de 2026Q1, 16 instituciones poseen acciones de Genfit SA, con un valor de mercado combinado de aproximadamente 22.36K, lo que representa el 0.04% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -215235.00.